IMR Press / EJGO / Volume 27 / Issue 1 / pii/2006102

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.


Neoadjuvant chemotherapy in gynecological cancers

Show Less
1 Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology, Faculty of Medicine, University of Hacettepe, Ankara, Turkey
2 Department of Obstetrics and Gynaecology,Faculty of Medicine, University of Firat Elazzg, Turkey
Eur. J. Gynaecol. Oncol. 2006, 27(1), 11–15;
Published: 10 February 2006

Neoadjuvant chemotherapy in gynecological cancers is an approach that is shown to have positive effects on survival. It increases the rate of resectability in ovarian and cervical cancers and thus contributes to survival. However, there are studies reporting that despite increasing operability, the approach does not make any changes in terms of survival. Nevertheless, no negative effects have been reported in studies conducted till today. Prospective and randomized well-designed studies that encompass a high number of cases and parameters, including cost-effectiveness, are needed in both types of cancers. Until the results of such studies are obtained, neoadjuvant chemotherapy may be taken into consideration as an alternative when conventional methods do not suffice. The number of studies concerning endometrial, vulvar and vaginal cancers are few in the area of neoadjuvant chemotherapy.

Gynecologic cancer
Neoadjuvant chemotherapy
Ovarian cancer
Cervical cancer
Vulvar cancer
Endometrial cancer
Back to top